Cardiol Therapeutics (NASDAQ:CRDL) and CERo Therapeutics (NASDAQ:CERO) Head to Head Comparison

CERo Therapeutics (NASDAQ:CERO) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CERo Therapeutics and Cardiol Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	2	0	0	1.67
Cardiol Therapeutics	1	0	1	0	2.00

CERo Therapeutics presently has a consensus target price of $45.00, suggesting a potential upside of 128,839.83%. Cardiol Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 542.86%. Given CERo Therapeutics’ higher probable upside, equities analysts clearly believe CERo Therapeutics is more favorable than Cardiol Therapeutics.

Profitability

This table compares CERo Therapeutics and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Cardiol Therapeutics	N/A	-217.53%	-153.67%

Volatility & Risk

CERo Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CERo Therapeutics and Cardiol Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30 million	($102.61)	0.00
Cardiol Therapeutics	N/A	N/A	-$26.77 million	($0.30)	-4.67

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Cardiol Therapeutics beats CERo Therapeutics on 6 of the 11 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.